BioSpace News Archive

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an amendment to the definitive collaboration and license agreement (the License Agreement) with an affiliate of Gurnet Point Capital (GPC), a private investment firm focused on the life sciences and medical technology sectors

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology’s (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021.

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration (FDA), stating that, as part of its ongoing review of the Company’s Biologic License Application (BLA) for teplizumab

Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that Jonathan Kennedy, President and Chief Executive Officer and Drew Davies, Executive Vice President and Chief Financial Officer will be presenting from 3:00 p.m. to 3:40 p.m. Eastern Time

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”) announces that at the Corporation’s Annual General Meeting (AGM) held today the Corporation’s shareholders voted to support all of the resolutions that came before the meeting.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 2021 and May 17-21, 2021.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab

the New York State Public Health and Health Planning Council approved a Certificate of Need application which allows the affiliation between Maimonides Medical Center and New York Community Hospital to continue to move forward.

Ryvu Therapeutics (WSE:RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the U.S. Food and Drug Administration, FDA, has placed a partial clinical hold on the first in human phase Ib

Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that its abstract entitled, “Vaccination with Polyclonal Antibody Stimulator (PAS) prevents pancreatic carcinogenesis in the KRAS mouse model” has been selected for presentation in a minisymposium at the AACR Annual Meeting 2021.